UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Amino acids are sensitive glucagon receptor‐specific biomarkers for glucagon‐like peptide‐1 receptor/glucagon receptor dual agonists

Diabetes, obesity & metabolism, 2020-12, Vol.22 (12), p.2437-2450

2020

Volltextzugriff (PDF)

A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice

European journal of medicinal chemistry, 2020-10, Vol.203, p.112496, Article 112496

2020

Volltextzugriff (PDF)

OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes

European journal of pharmacology, 2024-01, Vol.962, p.176215-176215, Article 176215

2024

Volltextzugriff (PDF)

Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors

Biochemical pharmacology, 2020-10, Vol.180, p.114150, Article 114150

2020

Volltextzugriff (PDF)

Oxyntomodulin regulates resetting of the liver circadian clock by food

eLife, 2015-03, Vol.4, p.e06253-e06253

2015

Volltextzugriff (PDF)

New Generation Oxyntomodulin Peptides with Improved Pharmacokinetic Profiles Exhibit Weight Reducing and Anti-Steatotic Properties in Mice

Bioconjugate chemistry, 2020-04, Vol.31 (4), p.1167-1176

2020

Volltextzugriff (PDF)

Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations

Proceedings of the National Academy of Sciences - PNAS, 2013-03, Vol.110 (13), p.5211-5216

2013

Volltextzugriff (PDF)

Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity

Peptides (New York, N.Y. : 1980), 2023-04, Vol.162, p.170955-170955, Article 170955

2023

Volltextzugriff (PDF)

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

International Journal of Obesity, 2006-12, Vol.30 (12), p.1729-1736

2006

Volltextzugriff (PDF)

Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists

Peptides (New York, N.Y. : 1980), 2023-03, Vol.161, p.170948-170948, Article 170948

2023

Volltextzugriff (PDF)

S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors

Life sciences (1973), 2021-04, Vol.270, p.119136-119136, Article 119136

2021

Volltextzugriff (PDF)

Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke

Experimental neurology, 2017-02, Vol.288, p.104-113

2017

Volltextzugriff (PDF)

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy

Molecular metabolism (Germany), 2022-12, Vol.66, p.101633-101633, Article 101633

2022

Volltextzugriff (PDF)

The Glucagon Receptor Is Involved in Mediating the Body Weight‐Lowering Effects of Oxyntomodulin

Obesity (Silver Spring, Md.), 2012-08, Vol.20 (8), p.1566-1571

2012

Volltextzugriff (PDF)

Distinct roles of the extracellular surface residues of glucagon-like peptide-1 receptor in β-arrestin 1/2 signaling

European journal of pharmacology, 2024-04, Vol.968, p.176419-176419, Article 176419

2024

Volltextzugriff (PDF)

Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure

The journal of clinical endocrinology and metabolism, 2015-12, Vol.100 (12), p.4541-4552

2015

Volltextzugriff (PDF)

Design of Potent and Proteolytically Stable Oxyntomodulin Analogs

ACS chemical biology, 2016-02, Vol.11 (2), p.324-328

2016

Volltextzugriff (PDF)

Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects

Organic & biomolecular chemistry, 2019-09, Vol.17 (33), p.776-7771

2019

Volltextzugriff (PDF)

( d-Ser 2)Oxm[mPEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions

Biochemical pharmacology, 2010-12, Vol.80 (11), p.1727-1735

2010

Volltextzugriff (PDF)

A new stable GIP–Oxyntomodulin hybrid peptide improved bone strength both at the organ and tissue levels in genetically-inherited type 2 diabetes mellitus

Bone (New York, N.Y.), 2016-06, Vol.87, p.102-113

2016

Volltextzugriff (PDF)

Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake

Frontiers in endocrinology (Lausanne), 2023-07, Vol.14, p.1217021-1217021

2023

Volltextzugriff (PDF)

Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs

Endocrinology (Philadelphia), 2009-04, Vol.150 (4), p.1712-1722

2009

Volltextzugriff (PDF)

Chemical polysialylation: Design of conjugated human oxyntomodulin with a prolonged anorexic effect in vivo

Biochimie, 2013-02, Vol.95 (2), p.264-270

2013

Volltextzugriff (PDF)

Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus

European journal of pharmacology, 2014-11, Vol.743, p.69-78

2014

Volltextzugriff (PDF)

DPP-IV-resistant, long-acting oxyntomodulin derivatives

Journal of peptide science, 2011-04, Vol.17 (4), p.270-280

2011

Volltextzugriff (PDF)

1 – 25 von 148

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(142)
Mit Volltextzugriff
(130)

Publikationsform

Artikel
(148)

Sprache

Englisch
(148)
Japanisch
(26)

Erscheinungsjahr

n.n

Thema

Science & Technology
(140)
Life Sciences & Biomedicine
(138)
Animals
(123)
Oxyntomodulin
(113)
Male
(65)
Endocrinology & Metabolism
(53)
Pharmacology & Pharmacy
(52)
Humans
(50)
Rats
(50)
Oxyntomodulin - Pharmacology
(49)
Glucagon-Like Peptides - Pharmacology
(45)
Glucagon
(42)
Mice
(38)
Biochemistry & Molecular Biology
(34)
Biological And Medical Sciences
(34)
Obesity
(30)
Peptide Fragments - Pharmacology
(29)
Eating - Drug Effects
(28)
Glucagon - Pharmacology
(27)
Glucagon-Like Peptide 1
(27)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Amino acids are sensitive glucagon receptor‐specific biomarkers for glucagon‐like peptide‐1 receptor/glucagon receptor dual agonists

A novel long-acting oxyntomodulin analogue eliminates diabetes and obesity in mice

OXM-104, a potential candidate for the treatment of obesity, NASH and type 2 diabetes

Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors

Oxyntomodulin regulates resetting of the liver circadian clock by food

New Generation Oxyntomodulin Peptides with Improved Pharmacokinetic Profiles Exhibit Weight Reducing and Anti-Steatotic Properties in Mice

Polar transmembrane interactions drive formation of ligand-specific and signal pathway-biased family B G protein-coupled receptor conformations

Emerging roles of oxyntomodulin-based glucagon-like peptide-1/glucagon co-agonist analogs in diabetes and obesity

Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial

Discovery of novel OXM-based glucagon-like peptide 1 (GLP-1)/glucagon receptor dual agonists

S3-2, a novel long-lasting oxyntomodulin derivative, exerts improvement on diabesity and renal injury through activating GLP-1 and glucagon receptors

Neurotrophic and neuroprotective effects of oxyntomodulin in neuronal cells and a rat model of stroke

BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy

The Glucagon Receptor Is Involved in Mediating the Body Weight‐Lowering Effects of Oxyntomodulin

Distinct roles of the extracellular surface residues of glucagon-like peptide-1 receptor in β-arrestin 1/2 signaling

Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure

Design of Potent and Proteolytically Stable Oxyntomodulin Analogs

Design, screening and biological evaluation of novel fatty acid chain-modified oxyntomodulin-based derivatives with prolonged glucose-lowering ability and potent anti-obesity effects

( d-Ser 2)Oxm[mPEG-PAL]: A novel chemically modified analogue of oxyntomodulin with antihyperglycaemic, insulinotropic and anorexigenic actions

A new stable GIP–Oxyntomodulin hybrid peptide improved bone strength both at the organ and tissue levels in genetically-inherited type 2 diabetes mellitus

Self-assembled GLP-1/glucagon peptide nanofibrils prolong inhibition of food intake

Investigation of Structure-Activity Relationships of Oxyntomodulin (Oxm) Using Oxm Analogs

Chemical polysialylation: Design of conjugated human oxyntomodulin with a prolonged anorexic effect in vivo

Comparison of stability, cellular, glucose-lowering and appetite supressing effects of oxyntomodulin analogues modified at the N-terminus

DPP-IV-resistant, long-acting oxyntomodulin derivatives

Suchergebnisse filtern